The Tumour Marker Group

Trine BjøroGroup leader
Trine Bjøro
Group leader

Immunoassay techniques have revolutionized the determination of clinically relevant proteins and peptides. The Tumour Marker Group at MBK is one of the few hospital laboratories that still develops, validates and introduces novel “in-house” assays into the clinical routine. We have more than 25 years of experience in the production of monoclonal antibodies (mAbs) for use in the construction of these specialized assays. Many of our mAbs have been licensed and are used in the manufacture of commercial assay kits that are in worldwide use. The challenges related to immunometric assays, particularly the problems caused by heterophilic antibodies or human anti-mouse antibodies have been thoroughly studied by the group and we have undertaken extensive studies on the incidence and prevention of interference in immunometric assays. We have developed assays for measuring therapeutic antibodies used in the treatment of patients with autoimmune diseases such as rheumatoid arthritis and Crohn’s disease, and participate in several national clinical trials. Recently, we have also developed assays for checkpoint (PD-1, CTLA-4) inhibitors, the new blockbuster drugs used in immunotherapy in oncology. By monitoring serum concentrations of these effective and expensive drugs, and identifying patients who produce neutralizing antibodies, clinicians may optimize the treatment for each individual patient.

 
Page visits: 1075